In the BioHarmony Drug Report Database
Rubraca (rucaparib camsylate) is a small molecule pharmaceutical. Rucaparib camsylate was first approved as Rubraca on 2016-12-19. It is used to treat ovarian neoplasms in the USA. It has been approved in Europe to treat ovarian neoplasms. It is known to target poly [ADP-ribose] polymerase 1. Rubraca’s patents are valid until 2035-08-17 (FDA).
Image (chem structure or protein)